

(FILE 'HOME' ENTERED AT 17:51:31 ON 10 FEB 2003)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, CANCERLIT' ENTERED AT 17:52:08 ON
10 FEB 2003

L1	0 S (AGGLUTINATION AFTER HEMOLYSIS)
L2	0 S (AGGLUT? AFTER LYSIS)
L3	1148 S AGGLUTINATION AND HEMOLYSIS
L4	272 S L3 AND AFTER?
L5	8 S L4 AND PARTICLE?

*updated
search
LYC 2/10/03*

L5 ANSWER 8 OF 8 MEDLINE
 AN 1998286723 MEDLINE
 DN 98286723 PubMed ID: 9625059
 TI Development and validation of an automated latex-enhanced immunoassay for prealbumin.
 AU Holownia P; Newman D J; Thakkar H; Bedzyk W D; Crane H; Olabiran Y; Davey C L; Price C P
 CS Department of Clinical Biochemistry, St. Bartholomew's and the Royal London School of Medicine & Dentistry, UK.
 SO CLINICAL CHEMISTRY, (1998 Jun) 44 (6 Pt 1) 1316-24.
 Journal code: 9421549. ISSN: 0009-9147.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199806
 ED Entered STN: 19980625
 Last Updated on STN: 19980625
 Entered Medline: 19980616
 AB The measurement of circulating prealbumin has been shown to be clinically useful in the assessment of nutritional status, both as an initial screen and in the monitoring of nutritional recovery. We describe a fully automated, noncompetitive, homogeneous, light-scattering immunoassay that has been developed for this analyte on a Dimension (Dade) analyzer. A sheep anti-prealbumin IgG fraction was covalently coupled to 40-nm chloromethyl styrene particles and, after the addition of sample, polyethylene glycol-assisted immunoagglutination was monitored by turbidimetry. The prealbumin working assay range was 8-550 mg/L at a sample volume of 2 microL and a reaction time of 6.5 min. When data were analyzed using ANOVA, total and within-run assay imprecision values (CVs) were 1-5%, and calibration and reagent stabilities were in excess of 40 days. Mean analytical recoveries were 102% +/- 4% (SD), and there was no lack of parallelism. Hemolysis, lipemia, and bilirubin did not interfere. Both plasma anticoagulated with heparin or EDTA and serum from plain or serum-separation tubes were acceptable as sample matrices. Comparison with the Beckman Array method gave a Passing and Bablok regression of: Dimension analyzer = 1.01Beckman + 7.1 (n = 103), using a common calibrator. We conclude that the prealbumin method is appropriate for clinical use according to the analytical criteria used in this study.
 CT Check Tags: Comparative Study; Human
 Agglutination
 Analysis of Variance
 Autoanalysis
 Drug Stability
 Immunoassay: IS, instrumentation
 Immunoassay: MT, methods
 Nephelometry and Turbidimetry
 *Prealbumin: AN, analysis
 Regression Analysis
 Reproducibility of Results
 Sensitivity and Specificity
 CN 0 (Prealbumin)

=>

L5 ANSWER 8 OF 8 MEDLINE
 AN 1998286723 MEDLINE
 DN 98286723 PubMed ID: 9625059
 TI Development and validation of an automated latex-enhanced immunoassay for prealbumin.
 AU Holownia P; Newman D J; Thakkar H; Bedzyk W D; Crane H; Olabiran Y; Davey C L; Price C P
 CS Department of Clinical Biochemistry, St. Bartholomew's and the Royal London School of Medicine & Dentistry, UK.
 SO CLINICAL CHEMISTRY, (1998 Jun) 44 (6 Pt 1) 1316-24.
 Journal code: 9421549. ISSN: 0009-9147.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199806
 ED Entered STN: 19980625
 Last Updated on STN: 19980625
 Entered Medline: 19980616
 AB The measurement of circulating prealbumin has been shown to be clinically useful in the assessment of nutritional status, both as an initial screen and in the monitoring of nutritional recovery. We describe a fully automated, noncompetitive, homogeneous, light-scattering immunoassay that has been developed for this analyte on a Dimension (Dade) analyzer. A sheep anti-prealbumin IgG fraction was covalently coupled to 40-nm chloromethyl styrene **particles** and, **after** the addition of sample, polyethylene glycol-assisted immunoagglutination was monitored by turbidimetry. The prealbumin working assay range was 8-550 mg/L at a sample volume of 2 microL and a reaction time of 6.5 min. When data were analyzed using ANOVA, total and within-run assay imprecision values (CVs) were 1-5%, and calibration and reagent stabilities were in excess of 40 days. Mean analytical recoveries were 102% +/- 4% (SD), and there was no lack of parallelism. **Hemolysis**, lipemia, and bilirubin did not interfere. Both plasma anticoagulated with heparin or EDTA and serum from plain or serum-separation tubes were acceptable as sample matrices. Comparison with the Beckman Array method gave a Passing and Bablok regression of: Dimension analyzer = 1.01Beckman + 7.1 (n = 103), using a common calibrator. We conclude that the prealbumin method is appropriate for clinical use according to the analytical criteria used in this study.
 CT Check Tags: Comparative Study; Human
 Agglutination
 Analysis of Variance
 Autoanalysis
 Drug Stability
 Immunoassay: IS, instrumentation
 Immunoassay: MT, methods
 Nephelometry and Turbidimetry
 *Prealbumin: AN, analysis
 Regression Analysis
 Reproducibility of Results
 Sensitivity and Specificity
 CN 0 (Prealbumin)

=>

5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 1999:498584 CAPLUS

DN 131:155525

TI Stabilization of hemoglobin-containing samples, dispersants for feces, and immunoassay of hemoglobins

IN Yoshizawa, Yukie; Okamura, Michio; Oka, Imao

PA Eiken Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM G01N033-53

ICS G01N033-72

CC 9-15 (Biochemical Methods)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11218533	A2	19990810	JP 1998-34127	19980130
PRAI	JP 1998-34127		19980130		

AB In immunoassay of Hb-contg. samples, e.g. feces for occult blood detection, with anti-Hb antibodies, Hbs are stabilized in the presence of enzymic Hb degrdn. products. The dispersants used for suspending feces samples contain the enzymic Hb degrdn. products. Hbs are detd. by immunoagglutination of insol. carrier **particles** immobilizing anti-Hb antibodies. A mixt. of pig blood and Na citrate was centrifuged and the sepd. pig erythrocytes were frozen and thawed repeatedly for **hemolysis**. The hemolyzed prepn. was treated with pepsin at 30.degree. for 1 h, neutralized, and then ultrafiltered to give a fraction with mol. wt. 5000-6000. Hb value of feces sample suspended in HEPES buffer contg. the above pig Hb degrdn. product by immunoagglutination method was 718 ng/mL just **after** sampling and 382 ng/mL **after** 24 h, vs. 739 and 122 ng/mL, resp., for feces sample suspended in HEPES buffer.

ST Hb immunoagglutination assay enzymic degrdn product stabilizer; feces dispersant Hb enzymic degrdn product stabilizer

IT Immunoassay
(**agglutination** test; immunoagglutination assay of Hbs using Hb enzymic degrdn. products as stabilizers)

IT Immunoassay
(immunoadsorption chromatog.; immunoagglutination assay of Hbs using Hb enzymic degrdn. products as stabilizers)

IT Feces
Urine analysis
(immunoagglutination assay of Hbs using Hb enzymic degrdn. products as stabilizers)

IT Hemoglobins
RL: ANT (Analyte); ANST (Analytical study)
(immunoagglutination assay of Hbs using Hb enzymic degrdn. products as stabilizers)

IT Antibodies
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(monoclonal, to human Hbs; immunoagglutination assay of Hbs using Hb enzymic degrdn. products as stabilizers)

IT Antibodies
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(to human Hbs; immunoagglutination assay of Hbs using Hb enzymic degrdn. products as stabilizers)

IT 9001-75-6, Pepsin
RL: CAT (Catalyst use); USES (Uses)
(immunoagglutination assay of Hbs using Hb enzymic degrdn. products as stabilizers)

(FILE 'HOME' ENTERED AT 17:51:31 ON 10 FEB 2003)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, CANCERLIT' ENTERED AT 17:52:08 ON
10 FEB 2003

L1	0 S (AGGLUTINATION AFTER HEMOLYSIS)
L2	0 S (AGGLUT? AFTER LYSIS)
L3	1148 S AGGLUTINATION AND HEMOLYSIS
L4	272 S L3 AND AFTER?
L5	8 S L4 AND PARTICLE?